C5 and paroxysmal nocturnal hemoglobinuria: A similar study was conducted in Europe, which reported that PNH symptoms persist despite C5 inhibitor therapy (eculizumab or ravulizumab) and patients with PNH experience greater fatigue and poorer health-related QoL compared to the European general population references [13].